Related Experiment Video
Updated: Jun 12, 2026
10:49
Antibiotic Dereplication Using the Antibiotic Resistance Platform
Published on: October 17, 2019
Abstract:
Fidaxomicin, an RNA polymerase inhibitor, is being developed by Optimer and Par Pharmaceuticals as a narrow-spectrum antibacterial for the treatment of Clostridium difficile infections. It is currently in phase III development with promising results so far. This review looks at the development history and scientific profile of this drug to date.
Insights
Fidaxomicin is a novel antibacterial drug targeting RNA polymerase, showing promise for treating Clostridium difficile infections. Ongoing phase III trials indicate positive outcomes for this narrow-spectrum antibiotic.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Clostridium difficile infections (CDI) pose a significant healthcare challenge.
- Existing treatments for CDI have limitations, driving the need for new therapeutic options.
Purpose of the Study:
- To review the development history of fidaxomicin.
- To outline the scientific profile of fidaxomicin.
- To discuss its potential as a narrow-spectrum antibacterial agent for CDI.
Main Methods:
- Literature review of published studies and clinical trial data.
- Analysis of fidaxomicin's mechanism of action as an RNA polymerase inhibitor.
- Examination of preclinical and clinical development stages.
Main Results:
- Fidaxomicin demonstrates a narrow spectrum of activity, primarily targeting Gram-positive bacteria.
- Phase III clinical trials have yielded promising results in the treatment of Clostridium difficile infections.
- The drug exhibits a favorable safety profile compared to broader-spectrum antibiotics.
Conclusions:
- Fidaxomicin represents a promising therapeutic candidate for Clostridium difficile infections.
- Its targeted mechanism and favorable profile may offer advantages in managing CDI.
- Further data from ongoing development will solidify its clinical utility.
Related Concept Videos
01:25Inhibitors of Bacterial Protein Synthesis
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:28Inhibitors of Bacterial DNA Synthesis
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
01:23Inhibitors of Gram-positive Cell Wall Synthesis
Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
01:27Combined Effects of Drugs: Synergism
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...